Macrophage-directed therapies have seen a recent explosion in investment with a series of new dedicated biotechs capitalizing on their
potential to rival PD1/PDL1 checkpoint inhibitors and T cell approaches in solid tumors.
At the inaugural Macrophage-directed Therapies Summit, we are bringing together the various approaches from CD47 blockades to CARmacrophages to provide the whole community with one dedicated forum. Address common drug development challenges to control the fluctuating phenotype of macrophage cells and improve efficacy with combination therapies.
Leave this summit with tangible actions to characterize the continuum of macrophage biology, measure the homing and trafficking of cells to the tumor site and improve targeting precision to prevent off-tumor toxicities.
Join the trailblazers from pharma, biotech and academia who are leading the translation of macrophage-directed therapies to learn, network and collaborate to successfully achieve clinical proof of concept.
Gold: Conference and 2 Workshops (Drug Developer): USD 3297.0,
Silver: Conference and 1 Workshop (Drug Developer): USD 2798.0,
Bronze: Conference Only (Drug Developer): USD 2299.0,
Workshops: Individual (Drug Developer): USD 599.0,
Gold: Conference and 2 Workshops (Academic): USD 1897.0,
Silver: Conference and 1 Workshop (Academic): USD 1498.0,
Bronze: Conference Only (Academic): USD 1099.0,
Workshops: Individual (Academic): USD 499.0
Speakers: Hong Wan, Chief Scientific Officer (ALEX Oncology), Robert Deans, Chief Technology Officer (Bluerock Therapeutics), Michael Klichinsky, Vice President, Discovery Research (Carisma Therapeutics), Leonard Reyno, Chief Medical Officer (Pionyr Immunotherapeutics), Courtney Crane, Principal Investigator (Seattle Children's Hospital), Bob Uger, Chief Scientific Officer (Trillium Therapeutics)